Emglif-M (12.5/500mg) – Empagliflozin + Metformin for Type 2 Diabetes
Pay in 3 Installments of
Rs.
53
JazzCash
easypaisa
NayaPay
Bank transfer
Cash on Delivery
Description
Emglif-M (12.5/500mg) is a prescription combination tablet containing Empagliflozin 12.5mg (SGLT2 inhibitor) and Metformin 500mg (biguanide) for the management of Type 2 diabetes mellitus. This dual mechanism provides superior glycaemic control compared to either agent alone.
Empagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the renal proximal tubules, increasing urinary glucose excretion and reducing blood glucose without causing hypoglycaemia. Metformin reduces hepatic gluconeogenesis, improves peripheral insulin sensitivity, and lowers fasting blood sugar. Together they also offer cardiovascular and renal protective benefits in T2DM patients.
Emglif-M is manufactured by Genix Pharma (Pvt.) Ltd. and requires a valid prescription. Send your prescription to Derma.pk via email: sales@derma.pk or WhatsApp: +92-320-5999650. Fast delivery to Lahore, Karachi, Islamabad, and all of Pakistan.
Use only as directed by your healthcare provider. Monitor blood glucose regularly and follow prescribed dietary guidelines.
Usage & Benefits
- Empagliflozin (SGLT2i) promotes renal glucose excretion for effective blood sugar lowering without hypoglycaemia
- Metformin reduces hepatic gluconeogenesis and improves peripheral insulin sensitivity
- Dual mechanism provides superior glycaemic control vs monotherapy
- Empagliflozin offers proven cardiovascular and renal protective benefits in T2DM
- Prescription required — use only as directed by your healthcare provider
How To Use
1. Take Emglif-M as prescribed by your healthcare provider.
2. Swallow the tablet whole with a full glass of water.
3. May be taken with or without food.
4. Monitor blood glucose regularly as advised by your doctor.
5. Maintain prescribed dietary guidelines and exercise routine.
6. Use only as directed by your healthcare provider.
FAQs
How does Emglif-M control blood sugar?
Emglif-M combines Empagliflozin (SGLT2i), which increases urinary glucose excretion, with Metformin, which reduces hepatic glucose production and improves insulin sensitivity — providing dual-mechanism Type 2 diabetes control.
Is a prescription required for Emglif-M?
Yes, Emglif-M is a prescription-only medicine. Please send your valid prescription to sales@derma.pk or via WhatsApp: +92-320-5999650.
What are the cardiovascular benefits of Empagliflozin?
Empagliflozin has demonstrated significant cardiovascular and renal protective benefits in clinical trials for Type 2 diabetes patients with established cardiovascular disease.
